This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2011 Jun 9;364(23):2261-2; author reply 2262-3.

doi: 10.1056/NEJMc1104826.

Olmesartan, microalbuminuria, and type 2 diabetes

Dimitrios Farmakis, Athanasios Aessopos

PMID: 21651398
DOI: 10.1056/NEJMc1104826

Comment

Olmesartan, microalbuminuria, and type 2 diabetes

Dimitrios Farmakis et al. N Engl J Med. 2011.

. 2011 Jun 9;364(23):2261-2; author reply 2262-3.

doi: 10.1056/NEJMc1104826.

Authors

Dimitrios Farmakis, Athanasios Aessopos

PMID: 21651398
DOI: 10.1056/NEJMc1104826

No abstract available

PubMed Disclaimer

Comment on

Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes.
Haller H, Ito S, Izzo JL Jr, Januszewicz A, Katayama S, Menne J, Mimran A, Rabelink TJ, Ritz E, Ruilope LM, Rump LC, Viberti G; ROADMAP Trial Investigators. Haller H, et al. N Engl J Med. 2011 Mar 10;364(10):907-17. doi: 10.1056/NEJMoa1007994. N Engl J Med. 2011. PMID: 21388309 Clinical Trial.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Atypon
- Ovid Technologies, Inc.
Medical
- MedlinePlus Health Information